Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Substance-related Disorders, Alcohol and Other Substance Use Prevention, Alcohol and Other Drug Use Disorders
Interventions: Thrive Digital Peer Platform (TDPP); Behavioral
Lead sponsor: Thrive Digital Health, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Solon, Ohio

Conditions: Parkinson Disease, Idiopathic Parkinson Disease
Interventions: [F-18] Fluorodopa Positron Emission Tomography, OM Meditation; Drug · Behavioral
Lead sponsor: Andrew Newberg; Other
Eligibility: 25 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: HIV Infections, Hepatitis B
Interventions: Not listed
Lead sponsor: Syneos Health; Other
Eligibility: 12 Years to 60 Years · Female only
Enrollment: 24,258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2099
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cyclosporine, irinotecan hydrochloride, phenobarbital; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Cigarette packaging, Data capture, Questionnaire administration; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 69 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: folic acid, lometrexol, paclitaxel; Dietary Supplement · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Impairment
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 58
States / cities: Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more

Conditions: Healthy
Interventions: sotrastaurin, placebo to sotrastaurin, Avelox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Coronary Artery Disease
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: Rapid City Regional Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rapid City, South Dakota

Conditions: AOD Effects and Consequences
Interventions: Alprazolam, Dextroamphetamine, Placebo; Drug · Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Smoking, Smoking Behaviors, Nicotine Dependence
Interventions: E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 2.4% Nicotine with Tobacco Flavor Only, E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 5% Nicotine with Tobacco Flavor Only, Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only, Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: Midazolam, AIN457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 5 more

Conditions: Osteoarthritis, Hip
Interventions: Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions: Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
Interventions: KB109, No intervention; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Healthy
Interventions: KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Solid Tumor
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Peng Wang, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions: Maskin Probe; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: CMS121, Placebo; Drug
Lead sponsor: Virogenics, Inc.; Industry
Eligibility: 19 Years to 85 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: PF-04958242, Itraconazole; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Search by objective public record fields.

Evaluating Feasibility, Acceptability, Usability, and an Initial Estimate of Effect of a Novel Training Platform on Peer Recovery Supporter Skill, Adherence, and Knowledge Gain-Phase I

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Effects of Filter Ventilation and Ventilation Information on Product Use Behaviors in Cigarette Smokers

Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

CAEB071 Thorough QTc Study in Healthy Volunteers

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Spectroscopic Imaging at 4T: A Drug Challenge Study

Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Systemic Steroids for Peripheral Nerve Blocks

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Drug-Drug Interaction Study of Qualaquin and Midazolam

VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation